Innova Therapeutics receives rare pediatric disease designation for osteosarcoma treatment
Innova Therapeutics Inc. has been granted rare pediatric disease designation by the FDA for its IVT-8086 osteosarcoma treatment.
“The FDA's rare pediatric disease designation of IVT-8086 for the treatment of osteosarcoma highlights the significant unmet medical needs for patients with this devastating and life-threatening disease,” Robert Ryan, PhD, CEO of Innova Therapeutics, said in the release. “IVT-8086 has the potential to become the first FDA-approved therapy for individuals with osteosarcoma in over 30 years.”
IVT-8086 is a humanized monoclonal antibody, designed to decrease tumor cell angiogenesis and cell migration, increase tumor cell apoptosis and rescue T cell exhaustion, according to a company press release. It has a high affinity to SFRP2, a novel anticancer therapeutic target in osteosarcoma tumor cells.
Read more about